




- (51) **International Patent Classification:**
A61K 39/42 (2006.01) *A61K 41/00* (2020.01)
- (21) **International Application Number:**
PCT/US2022/081966
- (22) **International Filing Date:**
21 December 2022 (21.12.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/265,816 21 December 2021 (21.12.2021) US
63/382,091 02 November 2022 (02.11.2022) US
- (71) **Applicant:** **HBVTECH, LLC.** [US/US]; 4539 Metropolitan Ct., Frederick, MD 21704 (US).
- (72) **Inventor:** **ZHANG, Yong-yuan;** 13901 Lullaby St., Germantown, MD 20884 (US).
- (74) **Agent:** **CHEN, Xi;** 10918 White Dahlia Dr., Woostock, MD 21163 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** METHODS FOR ELIMINATING HEPATITIS B VIRUS CCCDNA AND RCDNA AND THE HEPATITIS B DRUGS USED IN THE METHODS THEREOF

Fig. 11A

(57) **Abstract:** Disclosed herein is a method of treating human chronic hepatitis B virus infection by reducing or eliminating cccDNA in liver cell of an HBV infected patient for 3 months or longer.

[Continued on next page]

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*